Common Anti-Inflammatory Drugs Associated With Decreased Risk of Skin Cancer
|
By LabMedica International staff writers Posted on 12 Jun 2012 |
|
A new study has found an association linking the use of various nonsteroidal anti-inflammatory drugs (NSAIDs) with a decreased risk of two major types of skin cancer.
Researchers at Aarhus University Hospital (Aarhus, Denmark) undertook a retrospective, population-based case-control study of patients in Northern Denmark to examine the association between use of NSAIDs--including aspirin, ibuprofin, and naproxen--and the risk of squamous cell carcinoma (SCC), basal cell carcinoma (BCC), and malignant melanoma (MM). Analysis of medical records from northern Denmark from 1991 through 2009 identified 1,974 diagnoses of SSC, 13,316 diagnoses of BCC, and 3,242 diagnoses of MM. Drug use information (including prescription data) from these patients was compared with information from 178,655 individuals without skin cancer.
Statistical analyses indicated that individuals who filled more than two prescriptions for NSAIDs had a 15% decreased risk for developing SCC and a 13% decreased risk for developing MM than those who filled two or fewer prescriptions for the medications, especially when the drugs were taken for seven or more years or taken at high intensity. Taking NSAIDs did not seem to reduce the risk of developing BCC in general, although there was a 15% and 21% reduced risk of developing BCC on less-exposed sites (body areas other than the head and neck) when the drugs were taken long term or at high intensity, respectively.
The main SCC and MM risk-reducers in the study were nonselective NSAIDs and older COX-2 inhibitors (diclofenac, etodolac, and meloxicam). NSAIDs are thought to help prevent the development of cancer by inhibiting cyclooxygenase (COX) enzymes, which are known to be involved in carcinogenesis.
“We hope that the potential cancer-protective effect of NSAIDs will inspire more research on skin cancer prevention,” said first author Sigrún Alba Jóhannesdóttir, BSc, of the Department of Clinical Epidemiology at Aarhus University Hospital; “Also, [this] effect should be taken into account when discussing benefits and harms of NSAID use.”
Related Links:
Aarhus University Hospital
Researchers at Aarhus University Hospital (Aarhus, Denmark) undertook a retrospective, population-based case-control study of patients in Northern Denmark to examine the association between use of NSAIDs--including aspirin, ibuprofin, and naproxen--and the risk of squamous cell carcinoma (SCC), basal cell carcinoma (BCC), and malignant melanoma (MM). Analysis of medical records from northern Denmark from 1991 through 2009 identified 1,974 diagnoses of SSC, 13,316 diagnoses of BCC, and 3,242 diagnoses of MM. Drug use information (including prescription data) from these patients was compared with information from 178,655 individuals without skin cancer.
Statistical analyses indicated that individuals who filled more than two prescriptions for NSAIDs had a 15% decreased risk for developing SCC and a 13% decreased risk for developing MM than those who filled two or fewer prescriptions for the medications, especially when the drugs were taken for seven or more years or taken at high intensity. Taking NSAIDs did not seem to reduce the risk of developing BCC in general, although there was a 15% and 21% reduced risk of developing BCC on less-exposed sites (body areas other than the head and neck) when the drugs were taken long term or at high intensity, respectively.
The main SCC and MM risk-reducers in the study were nonselective NSAIDs and older COX-2 inhibitors (diclofenac, etodolac, and meloxicam). NSAIDs are thought to help prevent the development of cancer by inhibiting cyclooxygenase (COX) enzymes, which are known to be involved in carcinogenesis.
“We hope that the potential cancer-protective effect of NSAIDs will inspire more research on skin cancer prevention,” said first author Sigrún Alba Jóhannesdóttir, BSc, of the Department of Clinical Epidemiology at Aarhus University Hospital; “Also, [this] effect should be taken into account when discussing benefits and harms of NSAID use.”
Related Links:
Aarhus University Hospital
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Multi-Function Pipetting Platform
apricot PP5
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read more
Molecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Pathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read more
Technology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
